729 related articles for article (PubMed ID: 28494972)
41. Targeting CCR3 to Reduce Amyloid-β Production, Tau Hyperphosphorylation, and Synaptic Loss in a Mouse Model of Alzheimer's Disease.
Zhu C; Xu B; Sun X; Zhu Q; Sui Y
Mol Neurobiol; 2017 Dec; 54(10):7964-7978. PubMed ID: 27878757
[TBL] [Abstract][Full Text] [Related]
42. Relationships between flortaucipir PET tau binding and amyloid burden, clinical diagnosis, age and cognition.
Pontecorvo MJ; Devous MD; Navitsky M; Lu M; Salloway S; Schaerf FW; Jennings D; Arora AK; McGeehan A; Lim NC; Xiong H; Joshi AD; Siderowf A; Mintun MA;
Brain; 2017 Mar; 140(3):748-763. PubMed ID: 28077397
[TBL] [Abstract][Full Text] [Related]
43. Roles of O-GlcNAcylation on amyloid-β precursor protein processing, tau phosphorylation, and hippocampal synapses dysfunction in Alzheimer's disease.
Zheng BW; Yang L; Dai XL; Jiang ZF; Huang HC
Neurol Res; 2016 Feb; 38(2):177-86. PubMed ID: 27078700
[TBL] [Abstract][Full Text] [Related]
44. Effects of the superoxide dismutase/catalase mimetic EUK-207 in a mouse model of Alzheimer's disease: protection against and interruption of progression of amyloid and tau pathology and cognitive decline.
Clausen A; Xu X; Bi X; Baudry M
J Alzheimers Dis; 2012; 30(1):183-208. PubMed ID: 22406441
[TBL] [Abstract][Full Text] [Related]
45. Abeta exacerbates the neuronal dysfunction caused by human tau expression in a Drosophila model of Alzheimer's disease.
Folwell J; Cowan CM; Ubhi KK; Shiabh H; Newman TA; Shepherd D; Mudher A
Exp Neurol; 2010 Jun; 223(2):401-9. PubMed ID: 19782075
[TBL] [Abstract][Full Text] [Related]
46. The relation of synaptic biomarkers with Aβ, tau, glial activation, and neurodegeneration in Alzheimer's disease.
Wang YT; Ashton NJ; Servaes S; Nilsson J; Woo MS; Pascoal TA; Tissot C; Rahmouni N; Therriault J; Lussier F; Chamoun M; Gauthier S; Brinkmalm A; Zetterberg H; Blennow K; Rosa-Neto P; Benedet AL
Transl Neurodegener; 2024 May; 13(1):27. PubMed ID: 38802928
[No Abstract] [Full Text] [Related]
47. Linking amyloid-β and tau: amyloid-β induced synaptic dysfunction via local wreckage of the neuronal cytoskeleton.
Zempel H; Mandelkow EM
Neurodegener Dis; 2012; 10(1-4):64-72. PubMed ID: 22156588
[TBL] [Abstract][Full Text] [Related]
48. Yeast Model of Amyloid-β and Tau Aggregation in Alzheimer's Disease.
Moosavi B; Mousavi B; Macreadie IG
J Alzheimers Dis; 2015; 47(1):9-16. PubMed ID: 26402750
[TBL] [Abstract][Full Text] [Related]
49. Pre-synaptic C-terminal truncated tau is released from cortical synapses in Alzheimer's disease.
Sokolow S; Henkins KM; Bilousova T; Gonzalez B; Vinters HV; Miller CA; Cornwell L; Poon WW; Gylys KH
J Neurochem; 2015 May; 133(3):368-79. PubMed ID: 25393609
[TBL] [Abstract][Full Text] [Related]
50. Understanding the cause of sporadic Alzheimer's disease.
Zetterberg H; Mattsson N
Expert Rev Neurother; 2014 Jun; 14(6):621-30. PubMed ID: 24852227
[TBL] [Abstract][Full Text] [Related]
51. MicroRNA in Alzheimer's disease revisited: implications for major neuropathological mechanisms.
Dehghani R; Rahmani F; Rezaei N
Rev Neurosci; 2018 Feb; 29(2):161-182. PubMed ID: 28941357
[TBL] [Abstract][Full Text] [Related]
52. Chronic diabetic states worsen Alzheimer neuropathology and cognitive deficits accompanying disruption of calcium signaling in leptin-deficient APP/PS1 mice.
Zhang S; Chai R; Yang YY; Guo SQ; Wang S; Guo T; Xu SF; Zhang YH; Wang ZY; Guo C
Oncotarget; 2017 Jul; 8(27):43617-43634. PubMed ID: 28467789
[TBL] [Abstract][Full Text] [Related]
53. Untangling amyloid-β, tau, and metals in Alzheimer's disease.
Savelieff MG; Lee S; Liu Y; Lim MH
ACS Chem Biol; 2013 May; 8(5):856-65. PubMed ID: 23506614
[TBL] [Abstract][Full Text] [Related]
54. Ghrelin in Alzheimer's disease: Pathologic roles and therapeutic implications.
Jeon SG; Hong SB; Nam Y; Tae J; Yoo A; Song EJ; Kim KI; Lee D; Park J; Lee SM; Kim JI; Moon M
Ageing Res Rev; 2019 Nov; 55():100945. PubMed ID: 31434007
[TBL] [Abstract][Full Text] [Related]
55. Synaptic dysfunction in Alzheimer's disease: From the role of amyloid β-peptide to the α-secretase ADAM10.
Musardo S; Marcello E
Eur J Pharmacol; 2017 Dec; 817():30-37. PubMed ID: 28625569
[TBL] [Abstract][Full Text] [Related]
56. Unbiased high-content screening reveals Aβ- and tau-independent synaptotoxic activities in human brain homogenates from Alzheimer's patients and high-pathology controls.
Jiang H; Esparza TJ; Kummer TT; Brody DL
PLoS One; 2021; 16(11):e0259335. PubMed ID: 34748596
[TBL] [Abstract][Full Text] [Related]
57. Synaptic dysfunction in Alzheimer's disease.
Marcello E; Epis R; Saraceno C; Di Luca M
Adv Exp Med Biol; 2012; 970():573-601. PubMed ID: 22351073
[TBL] [Abstract][Full Text] [Related]
58. Screening of treatment targets for Alzheimer's disease from the molecular mechanisms of impairment by β-amyloid aggregation and tau hyperphosphorylation.
Lin LF; Luo HM
Neurosci Bull; 2011 Feb; 27(1):53-60. PubMed ID: 21270904
[TBL] [Abstract][Full Text] [Related]
59. Cognitive Decline in Preclinical Alzheimer's Disease: Amyloid-Beta versus Tauopathy.
Huber CM; Yee C; May T; Dhanala A; Mitchell CS
J Alzheimers Dis; 2018; 61(1):265-281. PubMed ID: 29154274
[TBL] [Abstract][Full Text] [Related]
60. [Molecular aspects of the pathogenesis and current approaches to pharmacological correction of Alzheimer's disease].
Kukharsky MS; Ovchinnikov RK; Bachurin SO
Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(6):103-114. PubMed ID: 26438898
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
